Other

Otsuka Pharmaceutical Company, Limited

Kowa Company Limited

Nippon Soda Co., Ltd.

Showa Yakuhin Kako Co., Ltd.

Mitsubishi Chemical Corporation

Kabushiki Kaisha Toyota Chuo Kenkyusho

Nagoya Industrial Science Research Institute

Bonac Corporation

Theravalues Corporation

Yoshiaki Kawashima

Showa Shinyaku Co., Ltd.

Toray Industries, Inc.

Toyo Sugar Refining Co., Ltd.

Takeuchi, Hirofumi

Hirofumi Takeuchi

Hidekazu Toyobuku

Koji Nakano

Toshiyuki Niwa

Toshio Inagi

Makoto Kanebako

Satoru Abe

Takeshi Shimotori

Yoji Ito

Hiroshi Miura

Yasuyuki Hira

Gentaro Nemoto

Yuichi Tozuka

Kohei Tahara

Masayuki Kanishi

Yoshiaki Fukushima

Chizuko Furo

Atsushi Imaizumi

Haruo Takahashi

Tsutomu Kajino

Ayaka Kobayashi

Yasuo Shinoda

Hideaki Hara

Hidekazu Toyofuku

Tsukasa Takahashi

Hitomi Ozawa

Tetsurou Handa

Takato Matsui

Yoshiko Takeuchi

Taimu Yamada

Mitsutaka Murata

Risako Onodera

Takashi Kometani

Yoshihisa Iida

Hiromasa Uchiyama

An object of the present invention is to provide a pharmaceutical tablet having high tensile strength and excellent in immediate disintegrability. The pharmaceutical tablet of the present invention is obtained by a direct compression method, and contains an active ingredient, a polyvinyl alcohol resin, and a plasticizer other than water, wherein a content of the plasticizer is 1 to 8 parts by weight with respect to 100 parts by weight of the polyvinyl alcohol resin.

Pharmaceutical tablet and production method thereof

The present invention provides a composition containing a single-stranded nucleic acid molecule consisting of a nucleotide sequence shown by 5'-AGCAGAGUACACACAGCAUAUACC-P-GGUAUAUGCUGUGUGUACUCUGCUUC-P-G-3&#x2032; (SEQ ID NO: 1) (in the sequence, P is a proline derivative linker represented by (I) in the DESCRIPTION) and a buffer, and having the following features: 

Composition stably containing single-stranded nucleic acid molecule that suppresses expression of TGF-&#x3b2;1 gene

Provided is a composition for oral intake, which exhibits improved oral absorbability of curcumin and/or an analog thereof and can be produced conveniently and inexpensively. A complex of curcumin and/or an analog thereof and a water-soluble cellulose derivative is disclosed.

Composition for oral intake

An object of the present invention is to provide a liposome which is excellent in intrapulmonary delivery controllability of drugs or genes and is suited for pulmonary administration. By modifying the surface of a liposome using a terminal hydrophobized polyvinyl alcohol and/or chitosan, retention of drugs or genes encapsulated in the liposome on the surface of lung tissue and transfer of drugs or genes into lung tissue can be properly modulated, and thus in vivo behavior can be controlled.

Transpulmonary liposome for controlling drug arrival

An object of the present invention is to provide a carrier composition for nucleic acid delivery, which can efficiently deliver a nucleic acid into cells when a nucleic acid such as siRNA is administered to animal-derived cells or animals, and also has low toxicity and high safety, and a composition for nucleic acid delivery containing the carrier composition and nucleic acid. A carrier for nucleic acid delivery is prepared by using (A) a diacylphosphatidylcholine, (B) at least one member selected from the group consisting of cholesterol and derivatives thereof, and (C) an aliphatic primary amine. Also, a composition for nucleic acid delivery is prepared by mixing the carrier for nucleic acid delivery with a nucleic acid.

Prompt nucleic acid delivery carrier composition

The invention provides a liposome for delivery to the posterior segment of the eye, comprising (A) a phospholipid, (B) a charged substance, and/or (C) a membrane-reinforcing substance; the liposome having a rigidity that provides the liposome with cell membrane permeability, and having a mean particle diameter of 1 &#x3bc;m or less; and a pharmaceutical composition for a disease in the posterior segment of an eye, comprising a drug encapsulated in the liposome. The liposome is delivered to the posterior segment of the eye by instillation, and is non-cytotoxic; and the pharmaceutical composition for a disease in the posterior segment of the eye comprises the liposome.

Liposome for delivery to posterior segment of eye and pharmaceutical composition for disease in posterior segment of eye

Provided is a method of producing hydroxyalkylcellulose microparticles, the method including generating a pulse shock wave, and supplying a hydroxyalkylcellulose aqueous solution to the pulse shock wave generation region, thereby crushing and drying the hydroxyalkylcellulose aqueous solution. According to the production method, hydroxyalkylcellulose microparticles having a volume-average particle size of at least 0.1 &#x3bc;m but less than 15 &#x3bc;m are obtained. By mixing the hydroxyalkylcellulose microparticles with a principal agent and subjecting the resulting mixture to a tablet compression, a solid preparation having excellent tensile strength and disintegration properties can be obtained.

Method of making hydroxyalkylcellulose microparticles

This invention relates to a nucleic acid complex with low toxicity and high safety that can maintain a nucleic acid molecule capable of RNA interference or translation inhibition, such as siRNA or the like, in a cell; and a nucleic acid delivery composition that can efficiently deliver the nucleic acid complex into a cell. A nucleic acid complex with low toxicity and high safety that can maintain a nucleic acid in a cell can be obtained by forming a complex using a nucleic acid molecule capable of RNA interference or translation inhibition and a cycloamirose. Further, by using a carrier comprising (A) a diacylphosphatidylcholine, (B) cholesterol and/or a derivative thereof, and (C) an aliphatic primary amine as a nucleic acid delivery carrier to introduce the nucleic acid complex into a cell, the safety, efficiency of intracellular delivery, and persistence of the nucleic acid in the cell can be further improved.

Nucleic acid complex and nucleic acid-delivering composition

Hydroxyalkylcellulose microparticles

The present invention provides a nucleic acid complex with low toxicity and high safety that can persistently maintain a nucleic acid, such as siRNA or the like, in a cell; and a nucleic acid delivery composition that can efficiently deliver the nucleic acid complex into a cell. A nucleic acid complex with low toxicity and high safety that can persistently maintain a nucleic acid in a cell can be obtained by forming a complex using a nucleic acid to be introduced into a cell, and a highly branched cyclic dextrin. Moreover, when a carrier comprising (A) a diacylphosphatidylcholine, (B) cholesterol and/or a derivative thereof, and (C) an aliphatic primary amine is used as a nucleic acid delivery carrier to introduce the nucleic acid complex into a cell, the safety, the efficiency of intracellular delivery, and the persistence of the nucleic acid in the cell can be further improved.

Nucleic acid complex and nucleic acid delivery composition

A composition containing an extremely poorly water-soluble drug and obtained by treating, with a supercritical fluid or subcritical fluid of carbon dioxide, a mixture comprising a porous silica material and the extremely poorly water-soluble drug; and its production process. The porous silica material has an average pore diameter in a range of from 1 to 20 nm, pores having diameters within &#xb1;40% of the average pore size account for at least 60% of a total pore volume of the porous silica material, and in X-ray diffractometry, the porous silica material has at least one peak at a position of diffraction angle (2&#x3b8;) corresponding to a d value of at least 1 nm. The composition according to the present invention, which contains the extremely poorly water-soluble drug, is excellent in the dissolution of the extremely poorly water-soluble drug.

Composition containing medicine extremely slightly soluble in water being excellent in eluting property and method for preparation thereof

A composition containing a very low water-soluble drug, which composition is produced by treating, with a supercritical or subcritical carbon dioxide fluid, a mixture containing a very low water-soluble drug and a porous material (exclusive of a porous silica material characterized in that the material has an average pore diameter of 1 to 20 nm, the total pore volume of the material that have a diameter falling within a range of &#xb1;40% of the average pore diameter account for 60% or more the volume of all the pores of the material, and, when subjected to X-ray diffractometry, the material exhibits one or more peaks at a diffraction angle (2&#x3b8;) corresponding to d of 1 nm or more); and a method for producing the composition. The very-low-water-soluble-drug-containing composition of the present invention ensures improved dissolution of the very low water-soluble drug.

Composition containing medicine extremely slightly soluble in water and method for preparation thereof

A granular medicine with slow drug-release characteristics that is sufficiently absorbed in the intestines, in which the granular medicine has a hollow spherical structure, a drug is dispersed in the shell, which mainly consists of an enteron-soluble polymer. The method for preparing the medicine includes the steps of: (a) mixing a hydrophilic or hydrophobic drug with an enteron-soluble polymer in a mixture of an aliphatic alcohol and a chlorohydrocarbon; and (b) pouring this mixture into water or an aqueous medium, and stirring the solution to precipitate the medicine.

Hollow granular medicine and its preparation

Growing community of inventors

Gifu, Japan

Hirofumi Takeuchi